Agonist mediated conformational changes of solubilized calf forebrain muscarinic acetylcholine receptors

Effects of N-ethylmaleimide on conformational equilibria in purified cardiac muscarinic receptors

Muscarinic receptors purified from porcine atria and devoid of G protein underwent a 9-27-fold decrease in their apparent affinity for the antagonists quinuclidinyl benzilate, N-methylscopolamine, and scopolamine when treated with the thiol-selective reagent N-ethylmaleimide. Their apparent affinity for the agonists carbachol and oxotremorine-M was unchanged. Conversely, the rate of alkylation by N-ethylmaleimide, as monitored by the binding of [(3)H]quinuclidinyl benzilate, was decreased by antagonists while agonists were without effect. The receptor also underwent a time-dependent inactivation that was hastened by N-ethylmaleimide but slowed by quinuclidinyl benzilate and N-methylscopolamine. The destabilizing effect of N-ethylmaleimide was counteracted fully or nearly so at saturating concentrations of each antagonist and the agonist carbachol. Similar effects occurred with human M(2) receptors differentially tagged with the c-Myc and FLAG epitopes, coexpressed in Sf9 cells, and extracted in digitonin/cholate. The degree of coimmunoprecipitation was unchanged by N-ethylmaleimide, which therefore was without discernible effect on oligomeric size. The data are quantitatively consistent with a model in which the purified receptor from porcine atria interconverts spontaneously between two states (i.e. R R*). Antagonists favor the R state; agonists and N-ethylmaleimide favor the comparatively unstable R* state, which predominates after purification. Occupancy by a ligand stabilizes both states, and antagonists impede alkylation by favoring R over R*. Similarities with constitutively active receptors suggest that R and R* are akin to the inactive and active states, respectively. Purified M(2) receptors therefore appear to exist predominantly in their active state.

Characterization of M1- and M2-muscarinic receptors in calf retina membranes

Muscarinic receptors are identified in bovine retina membranes by the specific binding of 1-[benzilic-4,4'-3H]-quinuclidinyl benzilate [3H]-QNB. Binding occurs to one population of non-cooperative binding sites: KD = 0.11 +/- 0.02 nM and Bmax = 0.61 +/- 0.07 pmol/mg protein. Competition binding curves of the M1-selective antagonist pirenzepine are shallow. Computer-analysis reveals the presence of 45 +/- 1% M1-receptors (high affinity sites for pirenzepine, Ki = 31 +/- 10 nM). The remaining low affinity sites (Ki = 1.0 +/- 0.3 microM) are denoted as M2-receptors. Competition binding curves with the agonist carbachol are shallow as well. 1 mM GTP causes a rightward shift and a steepening of the carbachol curve, whereas 1 mM N-ethylmaleimide (NEM) provokes a leftward shift and also a steepening of the curve. The GTP effect is abolished by NEM. Binding of the antagonists [3H]-QNB, atropine or pirenzepine is not modulated by GTP nor by NEM.

Different agonist binding properties of M1 and M2 muscarinic receptors in calf brain cortex membranes

The muscarinic antagonist 1-[benzilic 4,4'-3H]-quinuclidinyl benzilate [3H]-QNB) bound to a single class of non-cooperative sites in calf cerebral cortex membranes (KD = 0.29 nM and Bmax = 1.06 pM/mg protein). Computer-assisted analysis of the shallow pirenzepine/[3H]-QNB competition binding curves indicated that 68% of these sites were of the M1-subtype and the remaining 32% of the M2 subtype. Respective Ki-values for pirenzepine were 27 nM and 1.14 microM. Binding characteristics of the antagonist atropine and of the agonist carbachol for M2 were evaluated by performing competition binding with 0.5 nM [3H]-QNB in the presence of 2 microM pirenzepine. The binding characteristics for the M1 receptors were obtained indirectly by subtracting the curve for M2 from the total curve, or directly by competition binding with 0.3 nM [3H]-pirenzepine. Atropine competition curves were steep for M1 and M2 and were not affected by 1 mM GTP nor by 1 mM N-ethylmaleimide. The carbachol competition curve was shallow for M2. The steep curves for M1 indicate that this receptor subclass was only composed of low agonist affinity sites. GTP, which caused a rightward shift and a steepening of the carbachol competition curve for M2, did not affect the curves for M1. N-ethylmaleimide provoked a leftward shift and a steepening of the carbachol competition curve for M2 and abolished GTP modulation. A leftward shift was also observed for M1, but of a smaller magnitude (i.e. 3-4-fold for M1 compared to 17-fold for M2). These data suggest that, in calf brain cortex, M1 and M2 receptors show different susceptibility towards GTP and N-ethylmaleimide modulation.

Immunochemical studies of the muscarinic acetylcholine receptor

Muscarinic receptors have been purified from calf forebrain plasma cell membranes by affinity chromatography on a dexetimide-agarose gel. SDS-PAGE analysis showed a single 70 kDa band. Monoclonal antibodies have been prepared against these affinity purified 70 kDa protein(s). One antibody, M-35, immunoprecipitated up to 80% of digitonin-solubilized muscarinic receptors. M-35 had agonist-like effects on guinea-pig myometrium: it increased the intracellular cyclic GMP content, decreased prostaglandin-induced cyclic AMP accumulation and caused muscle contractions. The two first effects were inhibited by atropine. M-35 was used to visualize muscarinic receptors at the surface of human fibroblastic cells. In the particular cell line used, the receptors have a low affinity for pirenzepine, were negatively coupled to adenylate cyclase and mediated increase in the phosphatidyl-inositol breakdown.

Identification of M2 muscarinic receptors in membranes from bovine cerebral basal arteries

Muscarinic receptors were identified in membrane preparations from bovine cerebral arteries by the specific binding of [3H]-quinuclidinyl benzilate. The total amount of binding sites is relatively high: 1.5 pmol/mg protein, as compared to 0.91 pmol/mg for bovine cerebral cortex and 0.08 pmol/mg for heart muscle. In this study we show that the majority of these sites correspond to M2-receptors: 84% of the sites display low affinity for pirenzepine. In addition, GTP causes a rightward shift and steepening of the carbachol competition binding curve. In the presence of GTP, the alkylating reagent N-ethylmaleimide causes a 28-fold increase of the affinity for carbachol. This phenomenon is also observed on bovine heart membranes where muscarinic receptors are known to be of the M2 type. In contrast, muscarinic receptors in cerebral cortex, predominantly of the M1-type, show only a 4-fold increase in agonist affinity by N-ethylmaleimide. These findings suggest that the ability of N-ethylmaleimide to modulate the agonist affinity is an additional criterion for the characterization of muscarinic M2-type receptors.

Molecular distinction between calf heart and brain muscarine receptors: different N-ethylmaleimide modulation of agonist binding

Muscarinic acetylcholine receptors in calf heart and forebrain membranes were identified by binding of 1-[benzilic-4,4'-3H]quinuclidinyl benzilate ([3H]QNB). We were able to solubilise these receptors with a yield of 50% of the proteins by treatment of the membranes with digitonin. The existence of two or more receptor subclasses with different agonist affinity in the heart membranes was evidenced by the shallow carbachol/[3H]QNB competition binding curves. The receptors displayed only low agonist affinity, in the presence of GTP as well as after solubilisation. The alkylating reagent N-ethylmaleimide (NEM) caused a 70-fold increase in agonist affinity for the solubilised receptors whereas GTP was ineffective. A similar difference in affinity was observed for the membranes when agonist competition curves in the presence of NEM were compared to those in the presence of GTP. NEM caused only a 2- to 3-fold increase of the agonist affinity for solubilised brain cortex membranes. These data suggest that heart and brain muscarine receptors are structurally different.